Joseph Roberts - 12 Dec 2025 Form 3 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Controller
Signature
/s/ Grant Levine, attorney-in-fact
Issuer symbol
ARCT
Transactions as of
12 Dec 2025
Net transactions value
$0
Form type
3
Filing time
19 Dec 2025, 17:20:19 UTC
Next filing
19 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Roberts Joseph Controller C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10285 SCIENCE CENTER DRIVE, SAN DIEGO /s/ Grant Levine, attorney-in-fact 19 Dec 2025 0002101782

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ARCT Common Stock 2,001 12 Dec 2025 Direct
holding ARCT Common Stock 200 12 Dec 2025 Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 5,000 $8.00 Direct F1
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 5,000 $14.12 Direct F2
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 2,808 $99.29 Direct F3
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 6,492 $99.29 Direct F4
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 7,000 $34.57 Direct F5
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 7,000 $16.92 Direct F6
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 7,500 $28.88 Direct F7
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 1,000 $37.44 Direct F8
holding ARCT Stock Option (Right to Buy) 12 Dec 2025 Common Stock 9,000 $16.24 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on August 24, 2018.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 18, 2020.
F3 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
F4 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
F5 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 10, 2021.
F6 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 9, 2022.
F7 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 15, 2023.
F8 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 22, 2024.
F9 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 16, 2024.